Labcorp Holdings Inc. LH
Verdict: Sell. Fair value $233 against a price of $253 on 6 Jan 2026, 8% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income has shown extreme volatility, declining from $2.38B in 2021 to $0.42B in 2023, before.... Both Revenue and Net Income peaked in 2021 (at $13.14B and $2.38B respectively) and have not....
Main risks
- Severe Profitability Decline: Net income and FCF have collapsed by 68% and 59% respectively from their 2021 peak, indicating a sharp deterioration in underlying business profitability post-COVID.
- Negative Incremental Returns: A highly negative 3-year ROIIC of -362% suggests that capital invested over the past three years has been value-destructive in terms of EBIT generation, a major red flag for capital allocation.
- Elevated Leverage: A proxy Net Debt/EBITDA ratio of ~4.0x is high and could limit financial flexibility, especially given the recent decline in profitability.
- Net Income has shown extreme volatility, declining from $2.38B in 2021 to $0.42B in 2023, before...
- Intense competitive environment
- Net Income has shown extreme volatility, declining from $2.38B in 2021 to $0.42B in 2023, before partially recovering to $0.75B in 2024. This volatility, largely driven by the COVID-19 testing boom and subsequent normalization, makes reported earnings an unreliable indicator of the company's sustainable operational health. Operating Cash Flow has been more stable, highlighting a significant divergence between reported profit and cash generation.